Voyager Therapeutics

Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2014
Size (employees)
52 (est)
Voyager Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Key People at Voyager Therapeutics

Mark Kay

Mark Kay

Founder
Phillip D. Zamore

Phillip D. Zamore

Founder
Guangping Gao

Guangping Gao

Founder
Krystof Bankiewicz

Krystof Bankiewicz

Founder
Jeff Goater

Jeff Goater

Vice President of Business Development
James Geraghty

James Geraghty

Interim Chief Business Officer

Voyager Therapeutics Office Locations

Voyager Therapeutics has office in Cambridge
Cambridge, US

Voyager Therapeutics Metrics

Voyager Therapeutics Summary

Market capitalization

$299.8 m

Closing share price

$11.5
Voyager Therapeutics's current market capitalization is $299.8 m.

Voyager Therapeutics Financials

Voyager Therapeutics's revenue is $17.3 m in FY, 2015
FY, 2015

Revenue

$17.3 m

Net Income

($29.7 m)

Voyager Therapeutics Market Value History

We estimate that Voyager Therapeutics's current employees are approximately 46% female and 54% male.

Voyager Therapeutics Company Life

You may also be interested in